US · Healthcare · Medical Devices
EPS came in at 0.88 against a street estimate of 1.15 — a miss of 23.5%.
Analysts rate Penumbra Inc a buy (14 buy, 4 hold, 0 sell out of 18) with an average price target of $361.58.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.99% |
| Vanguard Capital Management, LLC | 4.30% |
| Vanguard Portfolio Management, LLC | 4.20% |
| HBK INVESTMENTS L P | 4.15% |
| State Street Corp | 3.01% |
| Millennium Management LLC | 2.79% |
| Baillie Gifford & Co Limited. | 2.13% |
| Geode Capital Management, LLC | 2.02% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-30 |
| Shareholder vote results · Q2 2026 | 2026-06-22 |
| Shareholder vote results · Q2 2026 | 2026-05-07 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Proxy statement · Q2 2026 | 2026-04-29 |
| Annual report FY2025 | 2026-02-25 |
Readable in the app.
| Announcement | Date |
|---|---|
| Boston Scientific to acquire Penumbra in merger agreement Boston Scientific Corporation is acquiring Penumbra, Inc. in an all-stock and cash deal announced January 14, 2026. Penumbra shareholders will receive merger consideration of either $374 cas | 2026-01-15 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Penumbra Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.